MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1
Authors
Keywords
MiR-199a, Paclitaxel, Drug resistance, Prostate cancer, YES1
Journal
WORLD JOURNAL OF UROLOGY
Volume 36, Issue 3, Pages 357-365
Publisher
Springer Nature
Online
2017-12-04
DOI
10.1007/s00345-017-2143-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract 4392: Yes1 is the key molecule for the resistance to trastuzumab in breast cancer, and dasatinib overcomes the resistance
- (2016) Hiromasa Yamamoto et al. CANCER RESEARCH
- Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer
- (2016) Lin Liu et al. FEBS Journal
- MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer
- (2015) Di Chen et al. CANCER LETTERS
- Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances
- (2014) Nishant S. Gandhi et al. JOURNAL OF CONTROLLED RELEASE
- Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
- (2014) S. Carlsson et al. BMJ-British Medical Journal
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell
- (2012) Ning Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
- (2012) Che-Ming Jack Hu et al. BIOCHEMICAL PHARMACOLOGY
- Abstract 1183: miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines
- (2012) Jon C. Henry et al. CANCER RESEARCH
- MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells
- (2012) Weiwei Cheng et al. FEBS Journal
- miR-34 – a microRNA replacement therapy is headed to the clinic
- (2012) Andreas G. Bader Frontiers in Genetics
- MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells
- (2010) Francesca Fornari et al. CANCER RESEARCH
- Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance
- (2010) Zhiwei Wang et al. DRUG RESISTANCE UPDATES
- Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
- (2009) Janaiah Kota et al. CELL
- MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN
- (2008) H. Yang et al. CANCER RESEARCH
- MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
- (2008) Tyler E. Miller et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells
- (2008) R Chen et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now